IFNA2 and chronic myelogenous leukemia, BCR-ABL1 positive: IFN-I is a cytokine secreted by most cells in response to viral infection, and has known immunostimulatory and anticancer properties [37]; specifically, the IFN-I subtype IFNα2 has been approved, alone and in combination with tyrosine kinase inhibitors (TKIs), for the treatment of CML [38].